The purpose of the study is to determine if repeated daily doses of T0903131 (INT131) Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes Mellitus.

Inclusion Criteria:

• Clinical Diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to enrollment
• Fasting Plasma Glucose between 126 and 240 mg/dL
• Hemoglobin-A1c (HbA1c) between 6.8% and 10.0%
• Fasting C-peptide > 0.8 ng/mL

Exclusion Criteria:

• Treatment with any pharmacotherapy for Type 2 Diabetes Mellitus within previous 6 weeks prior to screening
• Prior treatment with Thiazolidinedione, including Troglitazone, Rosiglitazone, pioglitazone
• BMI > 42 kg/m2
• Presence of any diabetic complications requiring chronic therapy
• Presence or history of any form of hepatic disease
• Serum creatinine > 1.8 mg/dL
• History of cardiac arrhythmias or abnormal cardiac electrophysiology
• Any reason that, in the Investigator's judgment, would have interfered with the ability of the subject to comply with the requirements of the protocol